January 10, 2025

In recent years, the research progress and clinical application of new drugs such as immunotherapy and targeting have greatly changed the treatment pattern of gastric cancer, continuously extending the survival time of patients. Some patients have even achieved long-term survival due to immunotherapy, and the chronic management of gastric cancer is gradually becoming a reality. For example, in the critical study RATIONALE-305, in which Trastuzumab was approved as a first-line treatment for gastric cancer, the 3-year overall survival rate reached 21%.

Immunotherapy helps achieve chronic management of gastric cancer

Significant progress has been made in the development of new drugs for gastric cancer, with multiple new drugs such as immunotherapy, targeted therapy, and antibody conjugated drugs (ADCs) entering clinical practice, bringing about significant changes in the treatment landscape for advanced patients. In the management process of advanced gastric cancer, we need to pay attention to patient stratification management and develop long-term and systematic treatment strategies to maximize patient survival time.

Teralizumab welcomes the full population medical insurance for first-line gastric cancer patients

The annual medical insurance negotiations can be said to be highly anticipated, which concerns the practical interests of patients, as economic factors are a very important factor affecting clinical medication choices. The results of the 2025 medical insurance negotiations have been implemented, and the indications for first-line gastric cancer with trastuzumab have been successfully included in medical insurance for the entire population. This is a significant benefit for both patients and clinical doctors.

For patients, chemotherapy combined with trastuzumab is a better first-line treatment option. The global data from the RATIONALE-305 study showed that the combination of chemotherapy and trastuzumab significantly prolonged patient survival compared to chemotherapy alone, with a median OS extended from 12.9 months to 15 months and a 21% reduction in mortality risk (HR=0.79).

The early research design is crucial for innovative drugs to go global. RATIONALE-305 research was designed with a focus on China and a global perspective. I hope to use China as a foundation and observe the efficacy of Trastuzumab in gastric cancer patients worldwide.

Reference source for industry information: Indications for first-line gastric cancer patients with trastuzumab